Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 240

1.

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.

Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Bladé J, Goldschmidt H, Weisel KC, Ramasamy K, Zweegman S, Spencer A, Huang JSY, Lu J, Sunami K, Iida S, Chng WJ, Holstein SA, Rocci A, Skacel T, Labotka R, Palumbo A, Anderson KC.

Blood Cancer J. 2020 Feb 13;10(2):17. doi: 10.1038/s41408-020-0273-x. Review.

PMID:
32054831
2.

Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study.

Kunacheewa C, Lee HC, Patel K, Thomas S, Amini B, Srour S, Bashir Q, Nieto Y, Qazilbash MH, Weber DM, Feng L, Orlowski RZ, Lin P, Manasanch EE.

Clin Lymphoma Myeloma Leuk. 2020 Jan 15. pii: S2152-2650(20)30037-9. doi: 10.1016/j.clml.2020.01.001. [Epub ahead of print]

PMID:
32037287
3.

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.

Du Z, Weinhold N, Song GC, Rand KA, Van Den Berg DJ, Hwang AE, Sheng X, Hom V, Ailawadhi S, Nooka AK, Singhal S, Pawlish K, Peters ES, Bock C, Mohrbacher A, Stram A, Berndt SI, Blot WJ, Casey G, Stevens VL, Kittles R, Goodman PJ, Diver WR, Hennis A, Nemesure B, Klein EA, Rybicki BA, Stanford JL, Witte JS, Signorello L, John EM, Bernstein L, Stroup AM, Stephens OW, Zangari M, Van Rhee F, Olshan A, Zheng W, Hu JJ, Ziegler R, Nyante SJ, Ingles SA, Press MF, Carpten JD, Chanock SJ, Mehta J, Colditz GA, Wolf J, Martin TG, Tomasson M, Fiala MA, Terebelo H, Janakiraman N, Kolonel L, Anderson KC, Le Marchand L, Auclair D, Chiu BC, Ziv E, Stram D, Vij R, Bernal-Mizrachi L, Morgan GJ, Zonder JA, Huff CA, Lonial S, Orlowski RZ, Conti DV, Haiman CA, Cozen W.

Blood Adv. 2020 Jan 14;4(1):181-190. doi: 10.1182/bloodadvances.2019000491.

4.

Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.

Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH.

Biol Blood Marrow Transplant. 2019 Dec 24. pii: S1083-8791(19)31674-X. doi: 10.1016/j.bbmt.2019.12.726. [Epub ahead of print]

PMID:
31881283
5.

Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation.

Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Saini N, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Ahmed H, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH.

Biol Blood Marrow Transplant. 2019 Nov 29. pii: S1083-8791(19)30834-1. doi: 10.1016/j.bbmt.2019.11.028. [Epub ahead of print]

PMID:
31786242
6.

Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.

Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SV.

J Clin Oncol. 2019 Oct 25:JCO1901740. doi: 10.1200/JCO.19.01740. [Epub ahead of print]

PMID:
31652094
7.

A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.

Lee HC, Shah JJ, Feng L, Manasanch EE, Lu R, Morphey A, Crumpton B, Patel KK, Wang ML, Alexanian R, Thomas SK, Weber DM, Orlowski RZ.

Blood Cancer J. 2019 Oct 1;9(10):80. doi: 10.1038/s41408-019-0240-6. No abstract available.

8.

A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

Lee HC, Shah JJ, Feng L, Morphey A, Johnson RJ, Wesson ET, Wang ML, Alexanian R, Thomas SK, Orlowski RZ, Weber DM.

Am J Hematol. 2019 Dec;94(12):E319-E322. doi: 10.1002/ajh.25633. Epub 2019 Oct 4. No abstract available.

PMID:
31489991
9.

Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis.

Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH.

Clin Cancer Res. 2019 Nov 15;25(22):6781-6787. doi: 10.1158/1078-0432.CCR-19-0706. Epub 2019 Sep 3.

PMID:
31481508
10.

Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma.

Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Olsem J, Crumpton B, Morphey A, Berkova Z, Feng L, Orlowski RZ.

Haematologica. 2019 Aug 14. pii: haematol.2019.225375. doi: 10.3324/haematol.2019.225375. [Epub ahead of print]

11.

A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis.

Manasanch EE, Han G, Mathur R, Qing Y, Zhang Z, Lee H, Weber DM, Amini B, Berkova Z, Eterovic K, Zhang S, Zhang J, Song X, Mao X, Morgan M, Feng L, Baladandayuthapani V, Futreal A, Wang L, Neelapu SS, Orlowski RZ.

Blood Adv. 2019 Aug 13;3(15):2400-2408. doi: 10.1182/bloodadvances.2019000300. Erratum in: Blood Adv. 2019 Sep 24;3(18):2712.

12.

Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years.

Bashir Q, Chamoun K, Milton DR, Khan M, Ahmed S, Mehta R, Popat UR, Kebriaei P, Nieto Y, Oran B, Ciurea SO, Hosing C, Khouri I, Patel K, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH.

Leuk Lymphoma. 2019 Dec;60(14):3536-3543. doi: 10.1080/10428194.2019.1633633. Epub 2019 Jul 8.

PMID:
31282244
13.

Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia.

Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK.

Ann Hematol. 2019 Sep;98(9):2233-2235. doi: 10.1007/s00277-019-03734-7. Epub 2019 Jun 26. No abstract available.

PMID:
31243571
14.

Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.

Tabchi S, Nair R, Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, Manasanch EE.

Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):560-569. doi: 10.1016/j.clml.2019.05.001. Epub 2019 May 17.

PMID:
31201134
15.

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.

Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, Goldschmidt H, Yang Z, Kimball AS, Dimopoulos M.

Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):522-530.e1. doi: 10.1016/j.clml.2019.04.018. Epub 2019 May 2.

16.

Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease.

Liu H, He J, Koh SP, Zhong Y, Liu Z, Wang Z, Zhang Y, Li Z, Tam BT, Lin P, Xiao M, Young KH, Amini B, Starbuck MW, Lee HC, Navone NM, Davis RE, Tong Q, Bergsagel PL, Hou J, Yi Q, Orlowski RZ, Gagel RF, Yang J.

Sci Transl Med. 2019 May 29;11(494). pii: eaau9087. doi: 10.1126/scitranslmed.aau9087.

17.

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators.

N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249.

PMID:
31141632
18.

Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated?

Elhammali A, Milgrom SA, Amini B, Gunther JR, Yoder A, Ludmir EB, Moon B, Weber DM, Thomas SK, Garg N, Manasanch EE, Patel KK, Orlowski RZ, Lee HC, Bird JE, Satcher R, Lin P, Pinnix CC, Dabaja BS.

Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e465-e469. doi: 10.1016/j.clml.2019.04.015. Epub 2019 May 2.

PMID:
31133526
19.

Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma.

Baljevic M, Orlowski RZ.

Expert Opin Drug Metab Toxicol. 2019 Jun;15(6):459-473. doi: 10.1080/17425255.2019.1621839. Review.

PMID:
31104525
20.

Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.

Mateos MV, Orlowski RZ, Ocio EM, Rodríguez-Otero P, Reece D, Moreau P, Munshi N, Avigan DE, Siegel DS, Ghori R, Farooqui MZH, Marinello P, San-Miguel J.

Br J Haematol. 2019 Sep;186(5):e117-e121. doi: 10.1111/bjh.15946. Epub 2019 May 15. No abstract available.

PMID:
31090915
21.

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.

Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH.

Lancet Haematol. 2019 May;6(5):e266-e275. doi: 10.1016/S2352-3026(19)30023-7. Epub 2019 Mar 22.

PMID:
30910541
22.

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC.

Leukemia. 2019 Apr;33(4):1058-1059. doi: 10.1038/s41375-019-0410-3.

PMID:
30842604
23.

Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.

Zhuang J, Shirazi F, Singh RK, Kuiatse I, Wang H, Lee HC, Berkova Z, Berger A, Hyer M, Chattopadhyay N, Syed S, Shi JQ, Yu J, Shinde V, Tirrell S, Jones RJ, Wang Z, Davis RE, Orlowski RZ.

Blood. 2019 Apr 4;133(14):1572-1584. doi: 10.1182/blood-2018-06-859686. Epub 2019 Feb 8.

PMID:
30737236
24.

New Drugs in Multiple Myeloma.

Kunacheewa C, Orlowski RZ.

Annu Rev Med. 2019 Jan 27;70:521-547. doi: 10.1146/annurev-med-112017-091045. Review.

PMID:
30691369
25.

Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome.

Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK.

Am J Hematol. 2019 Mar;94(3):E72-E74. doi: 10.1002/ajh.25375. Epub 2018 Dec 21. No abstract available.

PMID:
30548467
26.

Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.

Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Feng L, Berkova Z, Hildebrandt M, Orlowski RZ.

Lancet Haematol. 2018 Dec;5(12):e628-e640. doi: 10.1016/S2352-3026(18)30174-1.

PMID:
30501870
27.

Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs.

Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH.

Bone Marrow Transplant. 2019 Jul;54(7):1089-1093. doi: 10.1038/s41409-018-0392-1. Epub 2018 Nov 16.

PMID:
30446740
28.

Melphalan-based autologous transplant in octogenarian multiple myeloma patients.

Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH.

Am J Hematol. 2019 Jan;94(1):E2-E5. doi: 10.1002/ajh.25310. Epub 2018 Oct 31. No abstract available.

29.

Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191.

Ni H, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Hitoshi Y, Ansell SM, Treon SP, Thomas SK, Lee HC, Wang Z, Davis RE, Orlowski RZ.

Clin Cancer Res. 2018 Dec 15;24(24):6408-6420. doi: 10.1158/1078-0432.CCR-17-3265. Epub 2018 Aug 20.

30.

High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.

Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH.

Leuk Lymphoma. 2019 Feb;60(2):442-452. doi: 10.1080/10428194.2018.1485908. Epub 2018 Jul 22.

PMID:
30032678
31.

Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.

Afrough A, Saliba RM, Hamdi A, Honhar M, Varma A, Cornelison AM, Rondon G, Parmar S, Shah ND, Bashir Q, Hosing C, Popat U, Weber DM, Thomas S, Orlowski RZ, Champlin RE, Qazilbash MH.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2197-2203. doi: 10.1016/j.bbmt.2018.07.010. Epub 2018 Aug 9.

32.

Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials.

Ailawadhi S, Jacobus S, Sexton R, Stewart AK, Dispenzieri A, Hussein MA, Zonder JA, Crowley J, Hoering A, Barlogie B, Orlowski RZ, Rajkumar SV.

Blood Cancer J. 2018 Jul 6;8(7):67. doi: 10.1038/s41408-018-0102-7.

33.
34.

Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma.

Zhang X, Lee HC, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Singh RK, Lu J, Qian Y, Raina K, Coleman KG, Crews CM, Li B, Wang H, Hailemichael Y, Thomas SK, Wang Z, Davis RE, Orlowski RZ.

Leukemia. 2018 Oct;32(10):2224-2239. doi: 10.1038/s41375-018-0044-x. Epub 2018 Mar 27.

35.

Acute Pancreatitis Associated with Ixazomib in a Multiple Myeloma Patient.

Steiner RE, Orlowski RZ, Lee HC.

Acta Haematol. 2018;139(1):67-70. doi: 10.1159/000484655. Epub 2018 Feb 2.

PMID:
29402766
36.

Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma.

Wang H, Baladandayuthapani V, Wang Z, Lin H, Berkova Z, Davis RE, Yang L, Orlowski RZ.

Oncotarget. 2017 Dec 7;8(69):113858-113873. doi: 10.18632/oncotarget.23017. eCollection 2017 Dec 26.

37.

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC.

Leukemia. 2018 Feb;32(2):252-262. doi: 10.1038/leu.2017.329. Epub 2017 Nov 16. Review. Erratum in: Leukemia. 2019 Apr;33(4):1058-1059.

38.

Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.

Zhou L, Zhang Y, Sampath D, Leverson J, Dai Y, Kmieciak M, Nguyen M, Orlowski RZ, Grant S.

Br J Cancer. 2018 Feb 6;118(3):388-397. doi: 10.1038/bjc.2017.432. Epub 2017 Dec 14.

39.

C-reactive protein promotes bone destruction in human myeloma through the CD32-p38 MAPK-Twist axis.

Yang J, Liu Z, Liu H, He J, Yang J, Lin P, Wang Q, Du J, Ma W, Yin Z, Davis E, Orlowski RZ, Hou J, Yi Q.

Sci Signal. 2017 Dec 12;10(509). pii: eaan6282. doi: 10.1126/scisignal.aan6282.

40.

Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes.

Purushothaman A, Bandari SK, Chandrashekar DS, Jones RJ, Lee HC, Weber DM, Orlowski RZ.

Oncotarget. 2017 Aug 27;8(43):73723-73732. doi: 10.18632/oncotarget.20564. eCollection 2017 Sep 26.

41.

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.

Yan X, Clemens PL, Puchalski T, Lonial S, Lokhorst H, Voorhees PM, Usmani S, Richardson PG, Plesner T, Liu K, Orlowski RZ, Losic N, Jansson R, Ahmadi T, Lantz K, Ruixo JJP, Zhou H, Xu XS.

Clin Pharmacokinet. 2018 Apr;57(4):529-538. doi: 10.1007/s40262-017-0598-1.

42.

Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma.

Zhang Y, Zhou L, Leng Y, Dai Y, Orlowski RZ, Grant S.

Oncotarget. 2017 Aug 1;8(35):59476-59491. doi: 10.18632/oncotarget.19761. eCollection 2017 Aug 29.

43.

Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.

Goldschmidt H, Moreau P, Ludwig H, Niesvizky R, Chng WJ, Joshua D, Weisel K, Spencer A, Orlowski RZ, Feng S, Iskander KS, Dimopoulos MA.

Leuk Lymphoma. 2018 Jun;59(6):1364-1374. doi: 10.1080/10428194.2017.1376743. Epub 2017 Sep 22.

PMID:
28937327
44.

The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma.

Tu YS, He J, Liu H, Lee HC, Wang H, Ishizawa J, Allen JE, Andreeff M, Orlowski RZ, Davis RE, Yang J.

Neoplasia. 2017 Oct;19(10):772-780. doi: 10.1016/j.neo.2017.07.009. Epub 2017 Aug 30.

45.

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P.

Lancet Oncol. 2017 Oct;18(10):1327-1337. doi: 10.1016/S1470-2045(17)30578-8. Epub 2017 Aug 23. Erratum in: Lancet Oncol. 2017 Oct;18(10):e562.

PMID:
28843768
46.

A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.

Shah JJ, Kaufman JL, Zonder JA, Cohen AD, Bensinger WI, Hilder BW, Rush SA, Walker DH, Tunquist BJ, Litwiler KS, Ptaszynski M, Orlowski RZ, Lonial S.

Cancer. 2017 Dec 1;123(23):4617-4630. doi: 10.1002/cncr.30892. Epub 2017 Aug 17.

47.

Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.

Yao Z, Deng L, Xu-Monette ZY, Manyam GC, Jain P, Tzankov A, Visco C, Bhagat G, Wang J, Dybkaer K, Tam W, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Møller MB, Winter JN, Piris MA, Fayad L, Liu Y, Song Y, Orlowski RZ, Kantarjian H, Medeiros LJ, Li Y, Cortes J, Young KH.

Leukemia. 2018 Feb;32(2):353-363. doi: 10.1038/leu.2017.222. Epub 2017 Jul 12.

48.

A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center.

Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH.

Leuk Lymphoma. 2018 Feb;59(2):515-518. doi: 10.1080/10428194.2017.1344906. Epub 2017 Jul 3. No abstract available.

PMID:
28673185
49.

Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion.

Hao S, Lin P, Medeiros LJ, Fang L, Carballo-Zarate AA, Konoplev SN, Sargent RL, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Lu X.

Mod Pathol. 2017 Oct;30(10):1378-1386. doi: 10.1038/modpathol.2017.63. Epub 2017 Jun 30.

50.

Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma.

Voorhees PM, Gasparetto C, Moore DT, Winans D, Orlowski RZ, Hurd DD.

Clin Lymphoma Myeloma Leuk. 2017 Jul;17(7):424-432. doi: 10.1016/j.clml.2017.05.007. Epub 2017 May 10.

PMID:
28655599

Supplemental Content

Loading ...
Support Center